论文部分内容阅读
本文通过体内、外实验探讨β２受体激动剂舒喘灵（ＳＴＬ）对慢性阻塞性肺疾病（ＣＯＰＤ）患者Ｔ淋巴细胞功能的影响。结果表明：体外（１０－８～ＩＯ－４）ｍｏＬ／Ｌ舒喘灵对ＣＯＰＯ患者Ｔ淋巴细胞增殖转化、Ｔ淋巴细胞诱生白细胞介素Ⅱ（Ｉｌ－２）的活性及膜白细胞介素Ⅱ受体（ｍＩＬ－２Ｒ）表达均呈剂量依赖性抑制作用；体内用药组和对照组Ｔ淋巴细胞增殖指数，ｍＩＬ－２Ｒ吸收ＩＬ─２的百分率均有显著差异，Ｐ＜０．０５。而血清可溶性白细胞介素Ⅱ受体（ｓＩＬ－２Ｒ）的ＯＤ值Ｐ＞０．０５。提示β２受体激动剂抑制ＣＯＰＤ患者本来就低下的细胞免疫功能。
The aim of this study was to investigate the effects of β 2 -agonist STZ on T lymphocyte function in patients with chronic obstructive pulmonary disease (COPD) in vitro and in vivo. The results showed that in vitro (10-8 ~ 10-4) moL / L Shucu Ling of COPO patients with T lymphocyte proliferation, T lymphocyte induced interleukin Ⅱ (Il-2) activity and membrane interleukin Ⅱ (MIL-2R) in a dose-dependent manner. The proliferation index of T lymphocytes in vivo and the percentage of IL-2 up-regulated by mIL-2R in both groups were significantly different (P <0.05). While the serum soluble interleukin 2 receptor (sIL-2R) OD value of P> 0.05. This suggests that β2-agonists suppress the cellular immune function inherently lower in COPD patients.